Evidence mapPaperPMID 34638771Full record

ReviewInternational journal of molecular sciences2021

PPARγ and TGFβ-Major Regulators of Metabolism, Inflammation, and Fibrosis in the Lungs and Kidneys.

Gábor Kökény, Laurent Calvier, Georg Hansmann

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 116 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Genetic regulation of fatty acid content in adipose tissue.American journal of human genetics · 2026
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 3 countries.

Gábor KökényInstitute of Translational Medicine, Semmelweis University, 1089 Budapest, Hungary.
Laurent CalvierDepartment of Molecular Genetics, University of Texas (UT) Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0001-6437-2119
Georg HansmannPulmonary Vascular Research Center (PVRC), Hannover Medical School, 30625 Hannover, Germany.ORCID 0000-0003-0709-3935
Medizinische Hochschule Hannover · DESemmelweis University · HU

Funding

Deutsche Forschungsgemeinschaft HA4348/2-2Deutsche Forschungsgemeinschaft HA4348/6-2 KFO311German Federal Ministry of Education and Research BMBF 01KC2001BGerman Federal Ministry of Education and Research BMBF ViP+ program 03VP08053Hungarian Ministryof Innovation and Technologies ÚNKP Bolyai+ Scholarship UNKP-20-5-SE-3Magyar Tudományos Akadémia Bolyai ScholarshipSemmelweis University Innovation Center STIA-OTKA 137266/TMI/2020
6 · The paper itself

Abstract

Peroxisome proliferator-activated receptor gamma (PPARγ) is a type II nuclear receptor, initially recognized in adipose tissue for its role in fatty acid storage and glucose metabolism. It promotes lipid uptake and adipogenesis by increasing insulin sensitivity and adiponectin release. Later, PPARγ was implicated in cardiac development and in critical conditions such as pulmonary arterial hypertension (PAH) and kidney failure. Recently, a cluster of different papers linked PPARγ signaling with another superfamily, the transforming growth factor beta (TGFβ), and its receptors, all of which play a major role in PAH and kidney failure. TGFβ is a multifunctional cytokine that drives inflammation, fibrosis, and cell differentiation while PPARγ activation reverses these adverse events in many models. Such opposite biological effects emphasize the delicate balance and complex crosstalk between PPARγ and TGFβ. Based on solid experimental and clinical evidence, the present review summarizes connections and their implications for PAH and kidney failure, highlighting the similarities and differences between lung and kidney mechanisms as well as discussing the therapeutic potential of PPARγ agonist pioglitazone.

Indexed as

Signal TransductionAnimalsHumansKidneyLungPioglitazonePPAR gammaPulmonary Arterial HypertensionPulmonary FibrosisRenal InsufficiencyTransforming Growth Factor betaPioglitazonePPAR gammaPPARG protein, humanTransforming Growth Factor betainflammationkidney fibrosisPPARγproliferationpulmonary arterial hypertensionTGFβvascular injury

Identifiers

PMID34638771
PMCPMC8508998
OpenAlexW3202989371

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.